:: Library Catalog

Imagen de Portada

Guardado en:

Detalles Bibliográficos
Autores principales:	Pei‐Fu Chen, Franklin Dexter
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Pharmaceutical Statistics
Acceso en línea:	https://onlinelibrary.wiley.com/doi/10.1002/pst.2467
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Confidence Intervals for the Risk Difference Between Secondary and Primary Infection Based on the Method of Variance Estimates Recovery
por: Chao Chen, et al.
Publicado: (2024)

Confidence Intervals for Validation of Analytical Procedures Under ICH Q2 ( R2 )
por: Paul Faya, et al.
Publicado: (2025)

Methodological Approaches for the Estimation of Confidence Intervals on Partial Youden Index Under Verification Bias
por: Sihan Jia, et al.
Publicado: (2026)

Rejoinder to the letter: “Standard and reference‐based conditional mean imputation: Regulators and trial statisticians be aware!”
por: Marcel Wolbers, et al.
Publicado: (2024)

A Tobit Partly Linear Mixed and Mixture Cure Model for the Joint Analysis of Interval‐Bounded Longitudinal Measurements and Survival Times With Cure Proportion
por: Zhanfeng Wang, et al.
Publicado: (2026)

Robust Modestly Weighted Log‐Rank Tests
por: Dominic Magirr, et al.
Publicado: (2025)

New, Shorter Small‐Sample Intervals for Vaccine Efficacy
por: Mauro Gasparini, et al.
Publicado: (2026)

Prediction Intervals for Overdispersed Binomial Endpoints and Their Application to Toxicological Historical Control Data
por: Max Menssen, et al.
Publicado: (2025)

Average Hazard as Harmonic Mean
por: Yasutaka Chiba
Publicado: (2025)

CUSUMIN Combination: A Cumulative Sum Interval Design for Phase I Cancer Drug‐Combination Trials
por: Tomoyoshi Hatayama, et al.
Publicado: (2025)

Approximate Bayesian Analysis for Borrowing External Controls for Randomized Controlled Trials With Dynamic Borrowing and Covariate Balancing Adjustment
por: Jixian Wang, et al.
Publicado: (2025)

Comment on “Average Hazard as Harmonic Mean” by Chiba (2025)
por: Hajime Uno, et al.
Publicado: (2025)

PKBOIN‐12: A Bayesian Optimal Interval Phase I/II Design Incorporating Pharmacokinetics Outcomes to Find the Optimal Biological Dose
por: Hao Sun, et al.
Publicado: (2024)

The Wilcoxon–Mann–Whitney Estimand Versus Differences in Medians or Means
por: Linda J. Harrison, et al.
Publicado: (2025)

Futility Interim Analysis Based on Probability of Success Using a Surrogate Endpoint
por: Ronan Fougeray, et al.
Publicado: (2024)

An Adaptive Three‐Arm Comparative Clinical Endpoint Bioequivalence Study Design With Unblinded Sample Size Re‐Estimation and Optimized Allocation Ratio
por: David Hinds, et al.
Publicado: (2024)

Survival Analysis Without Sharing of Individual Patient Data by Using a Gaussian Copula
por: Federico Bonofiglio
Publicado: (2024)

A Weighted Geometric Average Hazard Ratio Based Sample Size Formula for Non‐Proportional Hazards and Its Application to a Smoothed Piecewise Model in Cancer Immunotherapy Trial Design
por: Qingyang Zhang, et al.
Publicado: (2025)

Evaluating Safety Rules in Ongoing Dose‐Escalation Trials Using BOIN : A Comparative Analysis of Criteria and Their Impact on Dose‐Level Safety Assessments
por: Stefan Englert, et al.
Publicado: (2026)

Personalized Treatment Selection for Multivariate Ordinal Scale Outcomes and Multiple Treatments
por: Chathura Siriwardhana, et al.
Publicado: (2025)

Using Propensity Score Weighting to Enhance the Operating Characteristics of Power Prior in Leveraging External Data to Augment a Traditional Clinical Study
por: Heng Li, et al.
Publicado: (2025)

Generalizing Treatment Effect to a Target Population Without Individual Patient Data in a Real‐World Setting
por: Hui Quan, et al.
Publicado: (2024)

Chauhan Weighted Trajectory Analysis of Combined Efficacy and Safety Outcomes for Risk–Benefit Analysis
por: Utkarsh Chauhan, et al.
Publicado: (2025)

Simultaneous Inference Using Multiple Marginal Models
por: Ludwig A. Hothorn, et al.
Publicado: (2024)

Bayesian Hierarchical Models for Subgroup Analysis
por: Yun Wang, et al.
Publicado: (2024)

Time‐to‐event estimands and loss to follow‐up in oncology in light of the estimands guidance
por: Jonathan M. Siegel, et al.
Publicado: (2024)

Getting (More Out of) Graphics—Practices and Principles of Data Visualisation. Data Science SeriesBy AntonyUnwin, Chapman & Hall/CRC, 2024. 446 pp. $ 74.99. ISBN: 978‐0‐36‐767399‐4
por: Wei Zhao
Publicado: (2025)

A Federated Data Analysis Approach for the Evaluation of Surrogate Endpoints
por: Dries De Witte, et al.
Publicado: (2025)

Bayesian Power‐Based Sample Size Determination for Single‐Arm Clinical Trials With Time‐to‐Event Endpoints
por: Go Horiguchi, et al.
Publicado: (2026)

A Tutorial on Improving RCT Power Using Prognostic Score Adjustment for Linear Models
por: Emilie Højbjerre‐Frandsen, et al.
Publicado: (2025)

Estimation of Treatment Policy Estimands for Continuous Outcomes Using Off‐Treatment Sequential Multiple Imputation
por: Thomas Drury, et al.
Publicado: (2024)

Sample Size Estimation Using a Partially Clustered Frailty Model for Biomarker‐Strategy Designs With Multiple Treatments
por: Derek Dinart, et al.
Publicado: (2024)

Mediation Analysis of Path‐Specific Effects in Randomised Clinical Trials With Repeatedly Measured Mediators and Outcomes
por: Martin Linder, et al.
Publicado: (2025)

Leveraging Two‐Stage δ Global Sensibility Analysis Method to Inform Parameter Estimation in PBPK Models
por: Marina Cuquerella‐Gilabert, et al.
Publicado: (2026)

Using Off‐Treatment Sequential Multiple Imputation for Binary Outcomes to Address Intercurrent Events Handled by a Treatment Policy Strategy
por: Sunita Rehal, et al.
Publicado: (2026)

A Dose‐Finding Design for Drug Combinations Using a Bayesian 4 Parameter Logistic Model With Penalised D‐Optimality
por: Maxine Ajimi, et al.
Publicado: (2026)

Target Aggregate Data Adjustment Method for Transportability Analysis Utilizing Summary‐Level Data From the Target Population
por: Yichen Yan, et al.
Publicado: (2025)

Using an early outcome as the sole source of information of interim decisions regarding treatment effect on a long‐term endpoint: The non‐Gaussian case
por: Leandro Garcia Barrado, et al.
Publicado: (2024)

Great Wall: A Generalized Dose Optimization Design for Drug Combination Trials Maximizing Survival Benefit
por: Yan Han, et al.
Publicado: (2025)

Applying Bias Correction Methods to Build Hybrid Controls Using Real‐World Patients for a Phase IIb Randomized Controlled Trial of Baricitinib for Rheumatoid Arthritis
por: Heather J. Litman, et al.
Publicado: (2025)